InMode (INMD) Competitors

Soleno Therapeutics (NASDAQ:SLNO) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.

Which has more risk & volatility, SLNO or INMD?

Soleno Therapeutics has a beta of -1.56, suggesting that its stock price is 256% less volatile than the S&P 500. Comparatively, InMode has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500.

Do institutionals & insiders hold more shares of SLNO or INMD?

97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 23.7% of Soleno Therapeutics shares are held by insiders. Comparatively, 6.9% of InMode shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor SLNO or INMD?

Soleno Therapeutics received 140 more outperform votes than InMode when rated by MarketBeat users. However, 75.48% of users gave InMode an outperform vote while only 71.22% of users gave Soleno Therapeutics an outperform vote.

Company	Underperform	Outperform
Soleno Therapeutics	Outperform Votes 297 71.22%	Underperform Votes 120 28.78%
InMode	Outperform Votes 157 75.48%	Underperform Votes 51 24.52%

Which has better valuation & earnings, SLNO or INMD?

InMode has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	N/A	N/A	-$38.99M	-$2.97	-12.39
InMode	$492.05M	2.94	$197.92M	$2.30	7.50

Do analysts prefer SLNO or INMD?

Soleno Therapeutics presently has a consensus price target of $55.60, suggesting a potential upside of 49.02%. InMode has a consensus price target of $32.80, suggesting a potential upside of 90.26%. Given Soleno Therapeutics' higher probable upside, analysts plainly believe InMode is more favorable than Soleno Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
InMode	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Is SLNO or INMD more profitable?

InMode has a net margin of 40.22% compared to InMode's net margin of 0.00%. Soleno Therapeutics' return on equity of 29.80% beat InMode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	N/A	-79.65%	-52.92%
InMode	40.22%	29.80%	27.02%

Does the media prefer SLNO or INMD?

In the previous week, InMode had 13 more articles in the media than Soleno Therapeutics. MarketBeat recorded 15 mentions for InMode and 2 mentions for Soleno Therapeutics. InMode's average media sentiment score of 1.17 beat Soleno Therapeutics' score of 0.13 indicating that Soleno Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soleno Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InMode	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InMode beats Soleno Therapeutics on 11 of the 17 factors compared between the two stocks.